SOPHIA

Stratification of obese phenotypes to optimize future obesity therapy
SOPHIA logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 17
Grant agreement number
875534

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
8 301 000
EFPIA in kind
6 466 250
Associated Partners
1 201 139
Other
9 156
Total Cost
15 977 545

Summary

Obesity affects 150 million people in Europe and 650 million worldwide. People with obesity are at a greater risk of health complications like heart disease, diabetes and cancer.

The aim of the SOPHIA project is to improve our ability to predict who will experience which complications, and who will respond best to different obesity treatments. Currently, this is not possible. Part of the project will focus in particular on the relationship between type 1 diabetes and weight, as a large proportion of people with type 1 diabetes is overweight or has obesity.

SOPHIA will link up and analyse data from different cohorts of people with obesity, and carry out in-depth qualitative studies with patients to identify their perceptions and perspectives on obesity diagnosis and treatment.

This will hopefully deliver insights on the variables that predict the risk of complications and responses to treatment.

People living with obesity will be involved in all aspects of the project via a Patient Advisory Board. Ultimately, the project results should provide the basis for treatment pathways that are accepted by patients, healthcare systems, researchers and clinicians alike.

More broadly, the project hopes to change the narrative around obesity, to make it more patient-centric and equitable and to underline that it is a chronic disease, not something people choose to live with.

Participants Show participants on map

EFPIA companies
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Medtronic International Trading SARL, Tolochenaz, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
Universities, research organisations, public bodies, non-profit groups
  • Centre Hospitalier Regional Et Universitaire De Lille, Lille, France
  • Consiglio Nazionale Delle Ricerche, Roma, Italy
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Fundacio Institut D'Investigacio Biomedica De Girona Doctor Josep Trueta, Salt, Spain
  • George Washington University Corporation, Washington Dc, United States
  • Goeteborgs Universitet, Gothenburg, Sweden
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • Lunds Universitet, Lund, Sweden
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • The European Association For The Study Of Obesity - Ireland Company Limited By Guarantee, Dublin, Ireland
  • The University Of Exeter, Exeter, United Kingdom
  • Universita Cattolica Del Sacro Cuore, Milan, Italy
  • Universitaet Ulm, Ulm, Germany
  • Universiteit Maastricht, Maastricht, Netherlands
  • University College Cork - National University Of Ireland, Cork, Cork, Ireland
  • University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland
  • University Of Dundee, Dundee, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Atturos Limited, Limerick Clare, Ireland
  • Lipotype, Dresden, Germany
  • Metabolon GMBH, Potsdam, Germany
  • Third-I, Vilvoorde, Belgium
Associated partners
  • Jdrf International, New York, United States
  • Obesity Action Coalition Inc, Tampa, United States
  • T1d Exchange Inc, Boston, United States
Third parties
  • Universidad De Navarra, Pamplona, Spain
  • Universita Degli Studi Di Roma Tor Vergata, Rome, Italy
Project coordinator
Carel W Le Roux
University College Dublin, National University Of Ireland, Dublin